This week HeartFlow raised $364.2 million in an IPO and is trading on Nasdaq under the ticker symbol “HTFL”. HeartFlow is a pioneer in using AI to identify coronary artery disease (CAD). HeartFlow's precision coronary care platform is the most widely adopted AI solution in US healthcare. It is used in over 1,500 hospitals across the US and has diagnosed heart disease in over 400,000 patients. The IPO was managed by JP Morgan, Morgan Stanley and Piper Sandler, Stifel, and Canaccord Genuity. The company has raised more than $1.2 billion in capital since NSF's initial investment in 2002. This IPO is an exciting milestone for AI in healthcare.
Conventional diagnostic methods often provide misleading information that can lead to undiagnosed disease, unnecessary procedures, and incorrect treatment plans. HeartFlow uses AI to transform a CCTA scan into a dynamic and personalized 3D model of the heart. This 3D model helps doctors assess anatomy and physiology to help diagnose disease and create personalized treatment plans for patients. HeartFlow is backed by more than 600 peer-reviewed publications. This technology represents a major advance in cardiovascular care, enabling earlier detection and better management of CAD through non-invasive, AI-powered diagnostics.
Image source: HeartFlow
HeartFlow's FDA-Approved Platform
HeartFlow's FDA-approved platform uses standard CT scan images to create personalized 3D models of patients' hearts, simulating blood flow to detect blockages non-invasively. These three analyses make up an integrated platform to provide improved AI-powered risk scoring to identify both symptomatic and asymptomatic patients at risk of heart attack, from a single CCTA scan.
No comments:
Post a Comment